[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

January 2017 - April 2015

Decade

Year

Issue

November 1, 2016, Vol 2, No. 11, Pages 1389-1511

In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2016;2(11):1389. doi:10.1001/jamaoncol.2015.3547
Viewpoint

Direct-to-Consumer Advertising of Prescription Drugs Can Inform the Public and Improve Health

Abstract Full Text
JAMA Oncol. 2016;2(11):1395-1396. doi:10.1001/jamaoncol.2016.2443

This Viewpoint argues in favor of cancer-related, direct-to-consumer advertising of prescription drugs.

Direct-to-Consumer Drug Advertising in Oncology Is Not Beneficial to Patients or Public Health

Abstract Full Text
JAMA Oncol. 2016;2(11):1397-1398. doi:10.1001/jamaoncol.2016.2463

This Viewpoint argues against cancer-related, direct-to-consumer advertising of prescription drugs.

Optimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer

Abstract Full Text
JAMA Oncol. 2016;2(11):1399-1400. doi:10.1001/jamaoncol.2016.3631

This Viewpoint summarizes recent findings on optimizing adjuvant chemotherapy and surgery for early- and late-stage breast cancer.

Highlights of Recent Findings on Quality-of-Life Management for Patients With Cancer and Their Survivors

Abstract Full Text
JAMA Oncol. 2016;2(11):1401-1402. doi:10.1001/jamaoncol.2016.3620

This Viewpoint highlights recent findings on quality-of-life management for patients with cancer and their survivors.

Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy

Abstract Full Text
JAMA Oncol. 2016;2(11):1403-1404. doi:10.1001/jamaoncol.2016.2450

This Viewpoint proposes a way of categorizing patients based on Tumor Immunity in the MicroEnvironment (TIME) and discusses its implications in cancer treatment.

The “Next Big Thing” in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design—Between the Lines

Abstract Full Text
JAMA Oncol. 2016;2(11):1405-1406. doi:10.1001/jamaoncol.2016.1782

This review examines the methodological approaches to studies on relapsed or refractory multiple myeloma treatments.

Editorial

Physician-Patient Communication—An Actionable Target for Reducing Overly Aggressive Care Near the End of Life

Abstract Full Text
JAMA Oncol. 2016;2(11):1407-1408. doi:10.1001/jamaoncol.2016.1948

Drawing the Line in Risk-Reducing Gynecologic Surgery in Women With a BRCA Mutation

Abstract Full Text
JAMA Oncol. 2016;2(11):1409-1411. doi:10.1001/jamaoncol.2016.1773

Routine Cancer Antigen 125 Surveillance—The Fatal Attraction of Testing

Abstract Full Text
JAMA Oncol. 2016;2(11):1412-1413. doi:10.1001/jamaoncol.2016.2032
Original Investigation

Determinants of Patient-Oncologist Prognostic Discordance in Advanced Cancer

Abstract Full Text
JAMA Oncol. 2016;2(11):1421-1426. doi:10.1001/jamaoncol.2016.1861

This survey study characterizes the frequency of differences in opinion about prognosis among patients with advanced cancer and their oncologists, and reasons for the differences.

Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer

Abstract Full Text
JAMA Oncol. 2016;2(11):1427-1433. doi:10.1001/jamaoncol.2016.1842

This cohort study examines the use of CA-125 tests and computed tomographic scans in clinical practice before and after a 2009 randomized clinical trial and estimates the economic effect of surveillance testing.

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations

Abstract Full Text
JAMA Oncol. 2016;2(11):1434-1440. doi:10.1001/jamaoncol.2016.1820

This multicenter cohort study accesses the risk for uterine cancer and distribution of specific histologic subtypes after risk-reducing salpingo-oophorectomy without hysterectomy among women with BRCA mutations.

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

Abstract Full Text
open access
JAMA Oncol. 2016;2(11):1441-1449. doi:10.1001/jamaoncol.2016.1828

This cohort study compares outcomes among men with metastatic castration-resistant prostate cancer with vs without preandrogen receptor signaling (ARS) inhibitor AR-V7 protein in circulating tumor cells, and interactions between AR-V7 status and taxane treatment.

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant NeoplasmsA Meta-analysis

Abstract Full Text
open access
JAMA Oncol. 2016;2(11):1452-1459. doi:10.1001/jamaoncol.2016.2129

This meta-analysis compares patient outcomes in phase 1 trials that used a biomarker selection strategy with those that did not.

Association of the Extent of Resection With Survival in GlioblastomaA Systematic Review and Meta-analysis

Abstract Full Text
JAMA Oncol. 2016;2(11):1460-1469. doi:10.1001/jamaoncol.2016.1373

This meta-analysis summarizes published estimates of the association between extent of glioblastoma multiforme resection and overall and progression-free survival.

Investigation of 2 Types of Self-administered Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer SurvivorsA Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2016;2(11):1470-1476. doi:10.1001/jamaoncol.2016.1867

This randomized clinical trial compares the effects of relaxing vs stimulating acupressure vs usual care on fatigue, sleep, and quality of life in women treated for breast cancer.

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast CancerA Systematic Review and Meta-analysis

Abstract Full Text
has active quiz
JAMA Oncol. 2016;2(11):1477-1486. doi:10.1001/jamaoncol.2016.1897

This systematic review and meta-analysis evaluates the effect of neoadjuvant endocrine therapy on response rate and the rate of breast conservation surgery for estrogen receptor–positive breast cancer.

Invited Commentary

AR-V7 Protein in Circulating Tumor Cells—The Decider for Therapy?

Abstract Full Text
JAMA Oncol. 2016;2(11):1450-1451. doi:10.1001/jamaoncol.2016.2360
Review

Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint InhibitorsA Review

Abstract Full Text
JAMA Oncol. 2016;2(11):1490-1495. doi:10.1001/jamaoncol.2016.2214

This narrative review discusses how genomic and transcriptomic tumor analysis can be used to select patients for therapy with immune checkpoint inhibitors.

JAMA Oncology Clinical Challenge

Waxing and Waning Pruritic Cutaneous Lesions Refractory to Antibiotic Treatment

Abstract Full Text
JAMA Oncol. 2016;2(11):1501-1502. doi:10.1001/jamaoncol.2016.2074

A man in his 30s reported a 2-year history of waxing and waning pruritic papules involving his left popliteus, contralateral popliteus, groin, and penis with minimal response to antibiotics. What is your diagnosis?

JAMA Oncology Clinical Evidence Synopsis

Fertility and Early Pregnancy Outcomes Following Conservative Treatment for Cervical Intraepithelial Neoplasia and Early Cervical Cancer

Abstract Full Text
JAMA Oncol. 2016;2(11):1496-1498. doi:10.1001/jamaoncol.2016.1839

This clinical evidence synopsis summarizes a Cochrane Systematic Review comparing the fertility and early pregnancy outcomes up to 24 weeks of gestation in women with a history of treatment vs those that have not received treatment.

Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents

Abstract Full Text
JAMA Oncol. 2016;2(11):1499-1500. doi:10.1001/jamaoncol.2016.1864

This clinical evidence synopsis summarizes a Cochrane systematic review addressing the role of iron supplementation in the treatment of patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents.

Research Letter

Current Status of Prostate Cancer Diagnosis and Management in the United States

Abstract Full Text
JAMA Oncol. 2016;2(11):1505-1507. doi:10.1001/jamaoncol.2016.1785

This study used a hospital-based national cancer registry to assess prostate cancer diagnosis and management trends in the United States.

Prevalence of Autoimmune Disease Among Patients With Lung CancerImplications for Immunotherapy Treatment Options

Abstract Full Text
JAMA Oncol. 2016;2(11):1507-1508. doi:10.1001/jamaoncol.2016.2238

This study examines the prevalence of autoimmune diseases in patients diagnosed with lung cancer.

Comment & Response

Extent of Resection and Survival in Glioblastoma Multiforme

Abstract Full Text
JAMA Oncol. 2016;2(11):1508-1509. doi:10.1001/jamaoncol.2016.3806

Extent of Resection and Survival in Glioblastoma Multiforme

Abstract Full Text
JAMA Oncol. 2016;2(11):1509. doi:10.1001/jamaoncol.2016.3809

Extent of Resection and Survival in Glioblastoma Multiforme—Reply

Abstract Full Text
JAMA Oncol. 2016;2(11):1509-1510. doi:10.1001/jamaoncol.2016.3812

Measuring the Real Clinical Impact of Randomized Clinical Trials in OncologyBeyond Citation Counts

Abstract Full Text
JAMA Oncol. 2016;2(11):1510-1511. doi:10.1001/jamaoncol.2016.1779

Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology—ReplyBeyond Citation Counts

Abstract Full Text
JAMA Oncol. 2016;2(11):1511. doi:10.1001/jamaoncol.2016.1772
Correction

Error in Author Name Tagging

Abstract Full Text
free access
JAMA Oncol. 2016;2(11):1511. doi:10.1001/jamaoncol.2016.4564

Incorrect Affiliations and Updated Supplement

Abstract Full Text
free access
JAMA Oncol. 2016;2(11):1511. doi:10.1001/jamaoncol.2016.4680

Error in Article End Matter

Abstract Full Text
free access
JAMA Oncol. 2016;2(11):1511. doi:10.1001/jamaoncol.2016.5053

Error in Figure

Abstract Full Text
free access
JAMA Oncol. 2016;2(11):1511. doi:10.1001/jamaoncol.2016.5130
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2016;2(11):1392. doi:10.1001/jamaoncol.2015.3548
×